224 related articles for article (PubMed ID: 21438852)
1. Intravitreal anti-VEGF drugs as adjuvant therapy in diabetic retinopathy surgery.
Montero JA; Ruiz-Moreno JM; Correa ME
Curr Diabetes Rev; 2011 May; 7(3):176-84. PubMed ID: 21438852
[TBL] [Abstract][Full Text] [Related]
2. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.
Zehetner C; Kirchmair R; Huber S; Kralinger MT; Kieselbach GF
Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630
[TBL] [Abstract][Full Text] [Related]
3. Review of anti-VEGF therapy in proliferative diabetic retinopathy.
Jardeleza MS; Miller JW
Semin Ophthalmol; 2009; 24(2):87-92. PubMed ID: 19373692
[TBL] [Abstract][Full Text] [Related]
4. Dose of intravitreal bevacizumab (Avastin) used as preoperative adjunct therapy for proliferative diabetic retinopathy.
Hattori T; Shimada H; Nakashizuka H; Mizutani Y; Mori R; Yuzawa M
Retina; 2010 May; 30(5):761-4. PubMed ID: 20453802
[TBL] [Abstract][Full Text] [Related]
5. Anti-VEGF therapy in proliferative diabetic retinopathy.
Abdallah W; Fawzi AA
Int Ophthalmol Clin; 2009; 49(2):95-107. PubMed ID: 19349790
[No Abstract] [Full Text] [Related]
6. Anti-VEGF therapeutic approaches for diabetic macular edema.
Khurana RN; Do DV; Nguyen QD
Int Ophthalmol Clin; 2009; 49(2):109-19. PubMed ID: 19349791
[No Abstract] [Full Text] [Related]
7. Treatment of diabetic retinopathy with anti-VEGF drugs.
Waisbourd M; Goldstein M; Loewenstein A
Acta Ophthalmol; 2011 May; 89(3):203-7. PubMed ID: 21044274
[TBL] [Abstract][Full Text] [Related]
8. Ghost cell glaucoma after intravitreal bevacizumab for postoperative vitreous hemorrhage following vitrectomy for proliferative diabetic retinopathy.
Liu L; Wu WC; Yeung L; Wang NK; Kuo YH; Chao AN; Chen KJ; Chen TL; Lai CC; Hwang YS; Chen YP
Ophthalmic Surg Lasers Imaging; 2010; 41(1):72-7. PubMed ID: 20128573
[TBL] [Abstract][Full Text] [Related]
9. A review of clinical trials of anti-VEGF agents for diabetic retinopathy.
Nicholson BP; Schachat AP
Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):915-30. PubMed ID: 20174816
[TBL] [Abstract][Full Text] [Related]
10. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR PROLIFERATIVE DIABETIC RETINOPATHY: A Systematic Review and Meta-Analysis.
Simunovic MP; Maberley DA
Retina; 2015 Oct; 35(10):1931-42. PubMed ID: 26398553
[TBL] [Abstract][Full Text] [Related]
11. [Anti-VEGF inhibitors and their role in the treatment of diabetic macular oedema].
Kakkassery V; Winterhalter S; Joussen AM
Klin Monbl Augenheilkd; 2010 Sep; 227(9):701-11. PubMed ID: 20845250
[TBL] [Abstract][Full Text] [Related]
12. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy.
Arimura N; Otsuka H; Yamakiri K; Sonoda Y; Nakao S; Noda Y; Hashiguchi T; Maruyama I; Sakamoto T
Ophthalmology; 2009 May; 116(5):921-6. PubMed ID: 19410951
[TBL] [Abstract][Full Text] [Related]
13. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
Sankar MJ; Sankar J; Mehta M; Bhat V; Srinivasan R
Cochrane Database Syst Rev; 2016; 2():CD009734. PubMed ID: 26932750
[TBL] [Abstract][Full Text] [Related]
14. Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy.
Qian J; Lu Q; Tao Y; Jiang YR
Retina; 2011 Jan; 31(1):161-8. PubMed ID: 20890241
[TBL] [Abstract][Full Text] [Related]
15. Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment.
Oshima Y; Shima C; Wakabayashi T; Kusaka S; Shiraga F; Ohji M; Tano Y
Ophthalmology; 2009 May; 116(5):927-38. PubMed ID: 19269033
[TBL] [Abstract][Full Text] [Related]
16. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections.
Frenkel MP; Haji SA; Frenkel RE
Arch Ophthalmol; 2010 Dec; 128(12):1523-7. PubMed ID: 21149773
[TBL] [Abstract][Full Text] [Related]
17. Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy.
Ishikawa K; Honda S; Tsukahara Y; Negi A
Eye (Lond); 2009 Jan; 23(1):108-11. PubMed ID: 17891057
[TBL] [Abstract][Full Text] [Related]
18. Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema: a report by the American Academy of Ophthalmology.
Ho AC; Scott IU; Kim SJ; Brown GC; Brown MM; Ip MS; Recchia FM
Ophthalmology; 2012 Oct; 119(10):2179-88. PubMed ID: 22917890
[TBL] [Abstract][Full Text] [Related]
19. Effects of intravitreally injected bevacizumab on vascular endothelial growth factor in fellow eyes.
Matsuyama K; Ogata N; Matsuoka M; Wada M; Nishimura T; Takahashi K
J Ocul Pharmacol Ther; 2011 Aug; 27(4):379-83. PubMed ID: 21810018
[TBL] [Abstract][Full Text] [Related]
20. [Results of an expert survey on VEGF inhibitors in ophthalmology].
Kühn T
Klin Monbl Augenheilkd; 2011 Jul; 228(7):607-12. PubMed ID: 21472638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
